AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

But Repare and Black Diamond still have rebuilding to do.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.